Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
ORGANIZATION
Kichiro Matsumoto Elected as New Chief of Japan Medical Association
Kichiro Matsumoto, an executive board member of the Japan Medical Association (JMA), was elected as the new president of the powerful doctors’ lobby on June 25, replacing Toshio Nakagawa, who had previously dropped a bid for his second term. Dr…
To read the full story
Related Article
- Pharma Eyes Riveted on JMA’s Stance on Off-Year Revision as New Chief Builds Ties with Govt
August 22, 2022
- Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
- JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
May 25, 2022
- JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
May 24, 2022
ORGANIZATION
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
- Labor Federation Files Request for 5% Drug Price Hike with Health Minister
November 28, 2025
- Japan PBSS Launches to Buttress Drug Discovery via Grassroots Networks
November 26, 2025
- Labor Group Presses Lawmakers to Reflect Rising Costs in Drug Prices
November 26, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…